MENU

BCDA Stock BioCardia (BCDA, $2.05) Stochastic Oscillator left the oversold zone on April 15, 2025

A.I.dvisor
at Tickeron.com
Loading...
BCDA - BioCardia Inc.
Stochastic signal
Bullish Trend
Odds of UP Trend
Tickeron
Stochastic signal
Price: $2.05
Daily change: +$0.07 (+3.54%)
Daily volume: 25K
Capitalization: $9.4M
Industry: Biotechnology
This is a signal that BCDA's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options. A.I.dvisor identified 65 similar cases where BCDA's stochastic oscillator exited the oversold zone, and of them led to successful outcomes. Odds of Success:

BCDA in upward trend: price may jump up because it broke its lower Bollinger Band on April 03, 2025

BCDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 40 cases where BCDA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 65 cases where BCDA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BCDA advanced for three days, in of 231 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 116 cases where BCDA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 31, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BCDA as a result. In of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BCDA turned negative on March 31, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

BCDA moved below its 50-day moving average on April 01, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BCDA crossed bearishly below the 50-day moving average on April 04, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCDA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.460) is normal, around the industry mean (13.662). P/E Ratio (0.000) is within average values for comparable stocks, (62.714). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.754). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (90.090) is also within normal values, averaging (248.452).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BCDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
BCDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical-stage regenerative medicine company, which develops novel therapeutics for cardiovascular diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
320 Soquel Way
Phone
+1 650 226-0120
Employees
20
Web
https://www.biocardia.com